1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,161 | 0,196 | 13:17 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.06. | Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC | 280 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 26, 2026 / Cantargia AB (publ) (STO:CANTA) today announced the publication of preclinical and clinical findings from the nadunolimab trial CANFOUR in the scientific... ► Artikel lesen | |
| 23.06. | Cantargia AB: Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital | 147 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE... ► Artikel lesen | |
| 11.06. | Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC | 222 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 11, 2026 / Cantargia AB (Publ) (STO:CANTA) today announced a KOL Call to be hosted in collaboration with H.C. Wainwright with leading subject matter experts Drs. Peter... ► Artikel lesen | |
| 10.06. | Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study | 295 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 10, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current... ► Artikel lesen | |
| 05.06. | Cantargia AB: Cantargia publishes Information Document regarding Rights Issue of Shares | 224 | GlobeNewswire (Europe) | Cantargia AB (publ) ("Cantargia" or the "Company") publishes an information document (the "Information Document") relating to the rights issue of shares of approximately SEK 124 million before deduction... ► Artikel lesen | |
| 03.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.06.2026 | 352 | Xetra Newsboard | Das Instrument 7V3 SE0006371126 CANTARGIA AB EQUITY wird ex Kapitalmassnahme gehandelt am 03.06.2026 The instrument 7V3 SE0006371126 CANTARGIA AB EQUITY is traded ex capital adjustment on 03.06.2026Das... ► Artikel lesen | |
| 28.05. | Cantargia AB to Host Webcast Covering Rights Issue, Loan Agreement, and Strategic Priorities | 362 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 28, 2026 / Cantargia (STO:CANTA) - With reference to the Company's press release on May 28, 2026, regarding the decision to conduct a rights issue in combination with... ► Artikel lesen | |
| 28.05. | Cantargia AB: Cantargia AB carries out a rights issue of SEK 124 million and enters into a loan agreement of up to SEK 75 million | 497 | GlobeNewswire (Europe) | Cantargia AB (publ) ("Cantargia" or the "Company") hereby announces that the board of directors has resolved to carry out a new share issue of approximately SEK 124 million with preferential rights... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 21.05. | Bulletin from the Annual General Meeting in Cantargia AB | 348 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 21, 2026 / Cantargia (STO:CANTA) - The Annual General Meeting of Cantargia AB (publ) on May 21, 2026 resolved in accordance with the following:To adopt the income statement... ► Artikel lesen | |
| 19.05. | Cantargia Publishes Interim Report for The First Quarter of 2026 | 393 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 19, 2026 / Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for the first quarter of 2026."The first quarter of 2026 reflects both strong... ► Artikel lesen | |
| 06.05. | Invitation to the Presentation of Cantargia's Interim Report for Q1 2026 | 327 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for Q1 2026 on Tuesday, May 19, 2026, at 07:00 a.m. CEST.In conjunction... ► Artikel lesen | |
| 27.04. | Cantargia Announces Early Results from Trial of Nadunolimab in MDS and AML | 384 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 27, 2026 / Cantargia AB (Nasdaq Stockholm:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced early... ► Artikel lesen | |
| 17.04. | Cantargia Announces AACR 2026 Presentation of Study Design and Supportive Pre-Clinical Data for Investigator-Initiated Nadunolimab Study in MSS CRC | 450 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (Nasdaq Stockholm:CANTA) today reported that the rationale and study design of the phase 1b/2 clinical trial... ► Artikel lesen | |
| 17.04. | Cantargia Publishes Annual Report 2025 | 266 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that the annual report for 2025 has been published. The Annual Report is attached to this press... ► Artikel lesen | |
| 17.04. | Notice of Annual General Meeting in Cantargia AB | 250 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ), reg. no. 556791-6019, are invited to the annual general meeting on Thursday, 21 May 2026... ► Artikel lesen | |
| 05.03. | Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference | 734 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 5, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargias management will participate in one-on-one meetings... ► Artikel lesen | |
| 23.02. | Cantargia to Participate in TD Cowen's Annual Healthcare Conference | 445 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 23, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargia's management will participate in and host 1-1 meetings... ► Artikel lesen | |
| 20.02. | Cantargia Publishes Full Year Report 2025 | 341 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 20, 2026 / Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) full year report for 2025 is now available on the company's web page www.cantargia.com/en/investors/financial-reports."Cantargia... ► Artikel lesen | |
| 06.02. | Invitation to the Presentation of Cantargia's Annual Results for 2025 | 375 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's annual results report for 2025 on Friday, February 20, 2026, at 07:00 a.m. CET.In... ► Artikel lesen | |
| 28.01. | Cantargia to Participate at Leerink Partners Global Healthcare Conference | 334 | ACCESS Newswire | LUND, SE / ACCESS Newswire / January 28, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargias management will participate in one-on-one... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,35 | -2,46 % | Burrys Short-Angriff bei Micron Technologies, BioNTechs Radikalkur und Strategic Resources - ein noch stiller Rohstoff-Player! | Während der unglaubliche Boom rund um die Künstliche Intelligenz gigantische Gewinne verspricht, ziehen erste dunkle Wolken am Horizont auf. Prominente Investoren wetten plötzlich gegen die noch, bzw.... ► Artikel lesen | |
| EVOTEC | 4,968 | -0,44 % | Enteignungsangst, Skalierung und neue Phantasien - Evotec, dynaCERT, Vonovia | Drei Unternehmen aus verschiedenen Sektoren stehen an entscheidenden Wendepunkten. Der erste Wert ist ein führender Immobilienkonzern, der nun massiv vom Wegfall politischer Enteignungsrisiken profitiert... ► Artikel lesen | |
| QIAGEN | 36,275 | -1,08 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 580,00 | -0,34 % | Regeneron expects Q2 pre-tax IPR&D charge of ~$127M | ||
| BRAIN BIOTECH | 2,800 | +0,72 % | EQS-Adhoc: BRAIN Biotech AG vereinbart neue revolvierende Kreditlinie mit der MP Beteiligungs-GmbH | EQS-Ad-hoc: BRAIN Biotech AG / Schlagwort(e): Kapitalmaßnahmen / bedeutender Kreditvertrag
BRAIN Biotech AG vereinbart neue revolvierende Kreditlinie mit der MP Beteiligungs-GmbH
13.07.2026... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| CARDIOL THERAPEUTICS | 0,906 | +2,84 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| CSL | 74,91 | -0,16 % | CSL shares are up 35% since early June. Is the recovery here to stay? | ||
| BURCON NUTRASCIENCE | 1,140 | -1,72 % | Stonegate, Inc.: Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) 4Q26 | Dallas, Texas--(Newsfile Corp. - June 26, 2026) - Burcon Nutrascience Corporation (TSX: BU): Stonegate Capital Partners updates their coverage on Burcon Nutrascience Corporation (TSX: BU). Burcon... ► Artikel lesen | |
| MANNKIND | 3,612 | +0,72 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,950 | 0,00 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,250 | -11,91 % | Oxford Nanopore shares plummet as warns of first half revenue miss | ||
| ADAPTIMMUNE THERAPEUTICS | 0,162 | 0,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| CODEXIS | 2,096 | +0,29 % | Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform | REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| CORMEDIX | 7,440 | +1,17 % | CorMedix, Inc.: U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin Patent Litigation | PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of... ► Artikel lesen |
CANTARGIA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -3,47 % bei einem Aktienkurs von 0,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.